~~<i id='45830055F4'><strike id='45830055F4'><tt id='45830055F4'><pre id='45830055F4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

leisure time

author：focus 2025-10-02 07:44:57 - browse：373

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： 7 more heat

hotspot

focus

entertainment

explore

focus

0:31FormerPresidentDonaldTrumpspeaksattheConservativePoliticalActionConference,CPAC2023,March4,2023,

WSS

The inclusion problem at the heart of rehabilitation research

Mass General, Mayo Clinic look to monetize custom

EF3 tornado rips through North Carolina amid extreme weather nationwide

FDA sets aggressive timeline for overhauling inspection procedures

Tocagen's brain cancer gene therapy trial continues. Investors worry

Why Congress must ban federal programs from using QALYs

entertainment

leisure time

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ending racial health disparities hinges on penalties, political will

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Microsoft launches AI tool for clinical documentation through Epic

Hepatitis C has a cure — but many Americans still lack access to it

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Apple is now the first public company to be valued at $3 trillion

Update the Apgar Score to remove skin color

Trump demands the U.S. pay no more for drugs than other countries … again

Divers poised to search for children washed away in Pennsylvania flash flood

focus

Dog Aging Project founders on what lies ahead after losing funding

Microsoft launches AI tool for clinical documentation through Epic

To bolster infectious disease surveillance, genomics powerhouses team up

Immunocompromised patients offer clues on chronic Covid

Study identifies new proteins linked to dementia risk 25 years later

Prior authorization reform is both possible and imperative

entertainment

explore

explore

focus